Comme pour beaucoup d’autres domaines, celui des soins de santé génère une quantité croissante de données et en devient de plus en plus tributaire1. Les applications qui utilisent l’intelligence artificielle (IA) peuvent offrir des possibilités de mieux utiliser les soins de santé. En effet, ceux-ci sont de plus en plus guidés par un environnement de données, ce qui pourrait changer la façon dont les soins de santé sont offerts aux Canadiens et Canadiennes.
Qu’est-ce que l’intelligence artificielle?
L’IA est une spécialité des sciences informatiques se spécialisant en développement de systèmes capables d’effectuer des tâches normalement effectuées par l’intelligence humaine, telles que la résolution de problèmes, le raisonnement ou le repérage. Le travail sur l’IA date des années 50. Il ne s’agit pas d’un nouveau concept, mais bien d’avancées dans la puissance et la connectivité des ordinateurs au cours des 20 dernières années qui ont mené au développement de la recherche et d’applications1,3. On prévoit que l’IA aura une incidence sur plusieurs secteurs des soins de santé, notamment sur l’optimisation des processus, la recherche préclinique, les voies de traitement clinique, et les applications informatiques visant directement le patient et la population3,6.
Portée de ce bulletin
En plus de ses applications existantes, l’IA représente une mine de possibilités pour les soins de santé. Ce bulletin se concentre sur ses applications cliniques qui pourraient avoir des répercussions sur les soins aux patients, dont des outils déjà sur la planche à dessin, en développement ou qui sont déjà utilisés par les prestataires de soins de santé. L’objectif du bulletin est de présenter aux lecteurs un aperçu des écrits scientifiques à ce sujet. Ce bulletin ne vise pas discuter de l’efficacité clinique ni de la rentabilité de chacune de ces technologies d’IA qui y sont présentées. Également, certaines applications non cliniques sont mentionnées brièvement. Nous n’avons pas inclus de revue de leurs incidences possibles en soins de santé.
(La suite de ce texte n'est disponible qu'en anglais)
These bulletins are not systematic reviews and do not involve critical appraisal or a detailed summary of study findings.
Rather, they present an overview of the technology and available evidence. They are not intended to provide recommendations for or against a particular technology.
Literature Search Strategy
A limited literature search was conducted using PubMed and the Cochrane Library (2018, Issue 2). Grey literature was identified by searching relevant sections of the Grey Matters checklist (https://www.cadth.ca/grey-matters). Search filters for health technology assessments, systematic reviews, and meta-analyses were applied. The search was limited to English- language documents published between January 1, 2013, and February 28, 2018. Targeted supplemental searches were also conducted in PubMed at authors’ requests.
A draft version of this bulletin was posted publicly for stakeholder review.
AI is an umbrella term encompassing a number of subfields and approaches.2 In health care, AI systems often include, but are not limited to, one or more of the following:
The health care sector has a historic interest in prediction, making a subset of AI — machine learning — of particular relevance, particularly for the detection of disease and for personalized treatment planning.7 Machine learning involves training an algorithm to perform tasks by learning from patterns in data rather than performing a task it is explicitly programmed to do.2 To train a machine learning program, data are typically divided into training sets (where a human indicates whether an outcome of interest is present or absent) and validation sets (where the system uses what it learns to indicate the presence or absence of outcomes of interest).7 Typically, machine learning approaches are used when the number of patient traits of interest is small.8
Support Vector Machine
A support vector machine is a type of machine learning that is used mainly to classify subjects into two groups,8 often used for the diagnosis or prediction of disease.8
Artificial Neural Networks
An artificial neural network is a method of mimicking the way the human brain learns, through its connection of neurons, using a computer model.3 This form of AI can evaluate complex relationships between inputs and outputs through a hidden layer (or layers) of calculations.8 The network adapts to the information that it is provided (such as images) and, through a series of layered calculations, learns on its own what features can be used to determine specified outputs such as the presence or absence of a condition.1,2,5,9
Deep learning is a form of artificial neural network with many hidden layers between inputs and outputs that allow the program to analyze complex data of various structures.8
In health care, a common form of deep learning is the convolutional neural network.8 Approaches to deep learning can be supervised, with the goal of accurately predicting known outcomes (such as the presence or absence of a disease)
from sets of labelled data, or unsupervised with the goal of summarizing or explaining patterns observed in a set of data.1
Natural Language Processing
Natural language processing (NLP) is a branch of AI concerned with understanding and interpreting human language.6,10,11
In health care, NLP could be used to analyze the content of electronic medical records or as an automated agent to respond to patient questions.6
Emergence of AI in Canada
The availability of powerful, low-cost computers has led to a burst of innovation in AI systems.12,13 In health care, this innovation is supported by the increased availability of data from sources such as electronic health records, clinical and pathological images, and wearable connected sensors. This data can be used to train algorithms and provide more opportunities for these systems to practice and learn.4,7,12 The current health care landscape in Canada has been noted to be conducive to the adoption of AI.13 For example, the Canadian Association of Radiologists (CAR) stated that, “The integrated nature of the Canadian health care system makes it ideal for pooling anonymized medical data from several institutions or provinces, which is required to improve and validate AI tools for patient management.”13
Past funding and research efforts have provided Canada with a robust network of AI labs, including hubs in Edmonton (Alberta Machine Intelligence Institute), Montreal (Institute Québecois d’intelligence artificielle), and Toronto (Vector Institute).3 This developing infrastructure is complemented by various networking and funding initiatives. For instance, the Canadian Institute for Advanced Research is leading a pan-Canadian strategy to promote collaboration between the provincial hubs.14 To attract and retain students, post-graduates, and researchers to these hubs, the federal government also provided a one-time funding of C$125 million to create the Pan-Canadian Artificial Intelligence Strategy through the Canadian Institute for Advanced Research in the 2017 budget.3 The next Collaborative Health Research Project (CHRP) competition has earmarked C$6 million to support collaborative projects on “Artificial Intelligence, Health and Society” with Tri-Agency funding provided through the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health Research, and the Social Sciences and Humanities Research Council of Canada.15 Additional funding and investment in AI is occurring both provincially and regionally across Canada and plays an important role in the development of the country’s AI ecosystem.16 Further integration of AI in the Canadian system was discussed in a 2017 report by the Senate’s Standing Committee on Social Affairs, Science and Technology, which outlined some of the challenges and opportunities for AI in Canada’s health care system.3
Regulatory Considerations and Standardization
A key question that has been raised is whether AI should be regulated as a distinct area, or whether existing regulated areas should incorporate considerations for AI.17
Health Canada has indicated that Canada’s Food and Drug Act and Medical Devices Regulations have already informed issuing of licenses to technologies that use AI.3 In April 2018, Health Canada announced the establishment of the Digital Health Review Division within the Therapeutic Products Directorate’s Medical Devices Bureau. The division is intended to allow for a more targeted review of rapidly changing and innovating digital health technologies, including AI technologies.18
Other countries, including the US19,20 and the UK,21 have started planning for the regulation of AI in health care. In April 2018, the FDA announced that it will develop a new regulatory framework for these AI applications.22 Of note, the FDA intends to apply its new Pre-Cert program to AI applications which would focus on the developer rather than the product and allow minor changes to software to be approved without the need for resubmissions, an issue of particular concern with self-learning and self-adapting software.22 The program is intended to go through pilot testing for products classified as software as a medical device in 2019.23
Regulation of specialized AI applications may require additional considerations. For example, CAR recommends that AI tools with radiology applications must consider the principles of evidence-based medicine and should receive the same level of clinical assessment as all other innovative drugs or devices before adoption.24 They advise that consideration is given to potential ethical, medicolegal, and bias-related issues associated with the use of AI tools.24 As well, the CAR working group suggests that all AI tools developed for diagnostic purposes should follow the Standards for Reporting Diagnostic Accuracy (STARD) guidelines when reporting studies of diagnostic accuracy.24 Similarly, the group also recommended that studies reporting predictive models should be compliant with the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) statement.24
As well, to ensure that the performance on training datasets is generalizable to target hospital sites, CAR recommends that communications on patient cohort criteria should be comprehensive and transparent.24 In addition, CAR encourages the development of standards for validating and testing processes for AI tools with an emphasis on stability of performance over different settings, equipment and protocols, and reproducible techniques.24
Privacy, ethical, and social issues are addressed in more detail in the Implementation Issues section of this report.
Who Might Benefit?
AI has the potential to improve patient care and the delivery of health services across a broad range of clinical specialties. Some specialties have incorporated AI for some time. In other cases, AI tools are just emerging or are in earlier stages of development. The next section of the report outlines some clinical specialty areas for which health technologies involving AI are being developed, studied, and incorporated into patient care.
Clinical Uses of Artificial Intelligence
Radiology, pathology, and dermatology are anticipated to be the first clinical specialties to experience large-scale change due to the incorporation of AI into work practices. These specialties have been targeted because their work involves the collection of data in the form of image interpretation and analysis.25 Beyond these disciplines, there are numerous AI-related developments for other clinical specialties. Some of the developments outlined involve multiple clinical specialties or illustrate AI applications that have potential relevance across numerous clinical areas. For simplicity, they are presented according to the clinical specialty that the AI tool has most direct impact upon.
Radiology and Imaging
Machine learning in radiology can be used to facilitate automated disease detection that enables clinicians to more quickly characterize disease.26 Machine learning has increased rapidly in the field of medical imaging, especially in the areas of computer-aided detection, image analysis,27 and radiomics ¾ the applied conversion of medical images into complex quantitative data, which can be analyzed to support diagnoses and develop new decision support systems.28,29
The current focus of AI in medical imaging is on assisting imaging professionals in the reading and interpretation of images. Recent studies suggest that AI can make predictions when interpreting images at a level of competence comparable to that of a physician.30 Given radiologist error rates at around 3% to 5% in image interpretations,31 AI may play an important role in preventing medical errors. This is because AI applications are able to process large amounts of data, without being affected by lapses in memory, emotional response, or fatigue.32 In addition to the interpretation and reading of imaging exams, AI tools may also help radiologists by coordinating and integrating information, identifying patients for screening examinations, prioritizing patients for immediate interpretation, and standardizing reporting.33,34
While AI in radiology is currently concentrated in the research domain,24 deep learning algorithms are anticipated to diffuse into widespread clinical use,33,35 as is evident by the FDA’s recent approval of two AI-driven technologies.36-38 As well, numerous manufacturers of imaging equipment are integrating AI into their medical imaging software systems.24 For example, one large device manufacturer has 400 patents and patent applications in the field of AI.35
There is a spectrum of thought regarding the role of AI in radiology. It is anticipated that over the next 10 years there will be a gradual conversion to AI that will have significant implications for the work of radiologists.39 The extent of the impact on radiology is unclear with some stakeholders predicting that AI tools will improve radiologist’s contribution to patient care, enhance their workflow, and make their work easier and more interesting.24 Others speculate that AI will one day supersede radiologists.34
As AI tools become more sensitive and are able to identify small image variances that are not visually discernible by the human eye, they may have the potential to enable earlier diagnosis of disease.40 This could lead to the identification of previously unrecognized image features that correlate with a patient’s prognosis and potentially guide treatment decisions that were previously not possible.34 AI can also be used to track treatment progress, and record changes in the size and density of tumours over time.41 This process can inform treatment decisions, and verify progress in clinical studies.41
Applications in Medical Imaging
In 2017 the FDA provided 510(k) clearance for the first machine learning application to be used in a clinical setting. The tool uses MRI to assist physicians in diagnosing heart problems by providing accurate measurements of the volume of each ventricle, allowing for more precise assessment.42 In 2018, the FDA permitted the marketing of AI enhanced clinical decision support software designed to analyze computed tomography (CT) results to notify providers of a patient’s potential stroke. The software is intended to benefit patients by reducing the time to treatment by notifying a specialist earlier in the emergency setting.36 Also in 2018, the FDA approved an AI tool to be used with X-ray by a physician to support reviews of imaging exams for the detection of wrist fractures.37
Researchers have leveraged machine learning and deep learning in radiology to create tools that can improve the diagnosis and classification of cancer, including the identification of pulmonary nodules with CT,27 polyp detection in CT colonography,27,43 screening for breast cancer,44 detection of microcalcification clusters (early signs of breast cancer) in mammography,27 and the detection of masses and whether they are classified as benign or malignant in mammography.27 AI is now being combined with computer-aided detection systems in mammography to improve diagnostic accuracy for the classification of breast cancer.45
Deep learning tools that automate extraction and classification of imaging features with speed and power are assisting in the diagnosis of stroke using neuroimaging with CT and MRI.46-52 Key areas of development are radiomics, image segmentation, and multimodal prognostication.46 On the CT front, a similar decision support tool to the one recently approved by the FDA is in development that automates the Alberta Stroke Program Early CT Score (ASPECTS) assessment tool for early ischemic changes.47 As well, AI is used with CT angiography to differentiate free-floating intraluminal thrombus from carotid plaque48 and to predict recovery after stroke by providing an accurate measure of cerebral edema severity, which may aid in early triaging of suitable stroke patients for craniectomy.49
With MRI, AI is being used to improve the overall image quality of scans, which due to time constraints of managing stroke patients, are usually done quickly and are of lower quality, making precise diagnosis a challenge.50 A new technique uses high-resolution scans of different patients taken previously to improve the image quality of new stroke patients.50 The technique fills in the space between the scanned slices so that an algorithm can confirm that the image looks similar to comparable high-quality scans. The data from the original image and the previous images are separated so that measurements can be compared against the actual image. Data from functional MRI may allow the classification of individual motor impairment after a stroke, which may play a role in predicting neurological outcomes and optimizing rehabilitation.51 As well, AI data are being used with MRI to identify the extent and volume of stroke lesions with the aim of reducing the amount of time and effort dedicated to this task.52
There are other imaging-related AI algorithms on the horizon53 For example, AI is combined with both X-ray and MRI to provide automatic delineation of tumours.54 In addition, AI is coupled with chest X-ray to improve tuberculosis diagnosis,26,55 and with positron emission tomography (PET) to assist in the early diagnosis of Alzheimer’s disease.56 AI is also used with MRI to identify multiple sclerosis patients who are likely to benefit from proactive treatment,57 to determine Parkinson’s disease using computer-based diagnosis of the brain,27,58 and to differentiate Parkinson’s disease from progressive supranuclear palsy.58 As well, AI is being used as a decision support tool in endoscopy to predict the pathology of lesions and prevent unnecessary polypectomy of non-cancerous polyps.59,60
Concurrent developments in medical imaging relate to AI tools that are intended to improve patient and clinician safety, and patient experience. These include applications that enable CT to be performed at ultra-low radiation dose, MRI exams that can be conducted in two-thirds of current time frames, and PET that uses radio-tracer dose reduction of up to 99%.61
Pathology is a clinical area in which AI innovations are emerging, albeit at a somewhat slower rate than radiology.25,62
Current interest in AI for pathology may, in part, be linked to the emergence of whole slide digital scanners and the interest in digital pathology (digitization of histology slides to produce high-resolution images).25,63 Use of AI in pathology may also be linked to the fact that digital pathology creates large volumes of data that can be used in algorithms to recognize predictive patterns.64 Given the world shortage of pathologists,65 AI may be welcome in this discipline, particularly given the potential to enhance patient safety and contribute to workflow efficiencies.64 To assist pathologists, AI may be leveraged to:
- automate some of the complex and time-consuming tasks involved in pathology such as object quantification, tissue classification based on morphology, and rare target identification.64
- determine personalized treatments for patients by using the data available to enable more personalized treatment decisions.26
- minimize the risk of misdiagnosis and the incorrect prescribing of medicines.66
- improve standardization and the consistency of decision-making.26
- facilitate the sharing of images to other readers to help reduce inter-reader variability.66
- speed up the process of image analysis.26
AI in combination with digital pathology can also promote telepathology (the practice of pathology at a distance) by allowing physicians in rural and remote communities to access and consult with specialized pathologists. These two technologies used together can also help reduce inter-reader variability amongst pathologists by allowing images to be easily shared so that a second reader can confirm findings.66,67 Incorporation of AI into digital pathology practices may enable identification of data in images that is not visually discernable by the human eye — such as molecular markers in tumours. Such findings could lead to new microclassifications of diseases, and support early diagnosis.33
Numerous organizations are developing pattern-recognition algorithms for use with digital pathology to help interpret features in tissue and make predictions about disease progression (such as metastasis and recurrence).25,26,67-69 In cases where cancer is present, AI software can classify the characteristics of the condition in terms of staging, grading, and differential diagnosis.67,68 One such tool is intended to assist pathologists by providing precise methods to differentiate malignant from benign cells, and to determine the most effective treatment for a patient. The tool is currently being used to detect breast, prostate, lung and colorectal cancers, but it is anticipated that, over time, it may have the ability to identify any solid tumour.26
AI software that integrates histology and genomic biomarkers has been designed to predict the overall survival of patients with brain tumours. The predictive accuracy of the software is reported to be comparable or exceed the accuracy of a human pathologist.69
AI has the potential to play a role in supporting dermatologists’ clinical decision-making for general skin conditions and specific cancers. Most of the current and emerging applications of AI in dermatology are aimed at diagnosing and preventing the onset of skin disease.70
For patients, innovations in AI may help to minimize unnecessary biopsies and increase the early detection of skin diseases.71 For clinicians, AI may be able to assist in the diagnosis of disease. Considering current workforce shortages in dermatology,70 AI may assist dermatologists in the management of demanding workloads and competing priorities.
AI enhanced software has been developed that can distinguish malignant melanomas from benign lesions. A recent study demonstrated that an AI algorithm was more accurate than 21 dermatologists participating in the study at identifying melanomas from non-cancerous lesions.72 In addition, AI has been shown to be capable of identifying some new lesion characteristics such as border demarcation features particularly in the identification of cancerous lesions, which are often subtle and difficult to determine using visual diagnosis,71 the primary method used to diagnose skin conditions.72
Machine learning is being used to analyze and track the changes and development of skin moles for the purpose of early detection of serious skin conditions. Individuals can use a mobile device to scan their body using an AI application to identify suspicious marks and send images to their dermatologist for further analysis.70 AI is also being used to diagnose acne, psoriasis, seborrheic dermatitis,73 and nail fungus.74
Genetics and Genomics
It is anticipated that AI may play a role in the further refinement of genomics-informed precision medicine.75,76 AI can identify patterns in large data sets to provide greater insight into how the human physiology reacts to different chemicals, viruses, and the environment, and to inform tailored treatment.75,76
Machine learning is being used to recognize patterns in DNA sequences, that may help predict a patient’s probability of developing an illness and identify underlying causes to facilitate the development of targeted therapies.76 Machine learning is also being used to help inform the design of potential drug therapies to identify the genetic causes of disease and help understand the mechanisms underlying gene expression.77
Liquid biopsies that incorporate AI are in development.78 They enable physicians to better predict patient outcomes by determining whether their current therapy is optimal or if an alternative therapy may be more beneficial to a patient.78 Liquid biopsies remove the need for invasive biopsy procedures by analyzing DNA from a blood sample. One such innovation is intended to predict relapse an average of seven months earlier than the current standard of care in patients diagnosed with cancer.79
AI may also be used to improve accuracy in gene editing (a method of altering DNA at the cellular or organism level).80 The use of large datasets and machine learning may, in the future, be able to predict optimal locations to edit DNA to alleviate suboptimal gene editing outcomes, enabling researchers to focus efforts on genes that are less likely to be of risk to patients.81 It is anticipated that this could prevent the genetic risk of developing a disease before it occurs by editing the genome of an egg, sperm, or embryo and thus lowering the risk of disease even before birth. Genome editing may also be able to correct mutations such as Huntington’s disease or cystic fibrosis. In the UK, genome editing of human embryos was approved by regulatory authorities in 2017,82 and in the US, gene editing research is also under way. However, before AI and gene editing can advance, important ethical, legal, and social considerations will need to be addressed. In the US, the National Academies of Sciences, Engineering, and Medicine recently released a report recommending to authorize the use of AI with gene editing under the condition that it is used exclusively to prevent severe diseases for which no existing treatments exists.83
Innovation in AI for oncology has been addressed elsewhere in this bulletin, in sections covering radiology, pathology, dermatology, and genomics. Innovations not yet addressed are covered here.
AI is increasing its presence in oncology especially in the field of cancer-oriented cognitive computing systems.84 Cognitive computing mimics the working of the human brain by applying machine learning algorithms to simulate human thought processes using data mining, pattern recognition, and natural language processing.85 It can be used for the purpose of helping physicians to plan personalized patient treatment plans86 by synthesizing vast amounts of information and integrating it into decision-making more quickly than humans. Cognitive computing combines patient information with research publications, ongoing research discoveries, clinical guidelines,87 evidence-based literature,88 and ongoing clinical trials89 into a single large database. This may help physicians to stay abreast of scientific literature, which according to current estimates would require 29 hours per working day.87 Cognitive computing is not exclusive to oncology and is being explored across other clinical specialties to assist clinicians in managing challenging workloads;90 expanding treatment options for patients;91 enhancing the speed and accuracy of diagnosis;84 improving treatment decisions;88 and assisting in the delivery of personalized, evidence-based treatment options.87 A study on one such device reported that it was in agreement with recommendations made by physicians 93% of the time for patients with rectal cancer and 81% of the time for patients with colon cancer, while providing them with more data to support their findings.86 Cancer-oriented cognitive computer systems may be of relevance to patients in rural and remote settings where cancer expertise is limited.88
Other potential future applications of AI in cancer may relate to the enhancement of cancer research through the development of cancer networks and registries and the identification of cost-efficiencies. As well, AI may provide new insight on the collection of data, particularly as it relates to epidemiologic trends, therapies for rare cancers, treatment pathways, cancer etiologies, new associations with particular cancers, and therapeutic results and prognosis.88
Many AI algorithms for neurology have been developed to predict the development of disease using neuroimaging56 and these developments have been alluded to in the Radiology section of this report. Beyond neuroimaging, it is anticipated that machine learning holds promise in advancing the field of neuroscience. It has been suggested that AI applications in neuroscience may have the potential to support large-scale hypothesis generation, as well as provide insight on interactions, structure, and mechanisms of the brain and behaviour.92
In the area of stroke, the incorporation of AI algorithms that recognize the early warning signs of stroke through movement detection devices that can discriminate between normal resting and stroke-related paralysis are being used for early stroke prediction.93,94 As well, machine learning can be used to predict three-month outcomes in patients with acute ischemic stroke by examining correlations between physiological parameters of patients during the first 48 hours after stroke onset, which may play an important role in the early clinical treatment of patients.95
Researchers have demonstrated how a machine learning algorithm can be used to assess the extent of severity of Parkinson’s disease by developing a tool that can be used with a smartphone, to generate a Parkinson’s disease score that is intended to objectively weigh measures of disease severity. The score is used as an adjunct to standard Parkinson’s disease measures and can provide frequent and objective assessments in the real-world setting that could be used to improve clinical care and evaluate the effectiveness of novel therapeutics.96
AI is also being used in patients with spinal cord injury to provide prognostic evaluation and predict outcomes. An algorithm has been developed that provides data on patient-specific motor defects that can be used with a robot-assistive rehabilitation harness to assist people in learning to walk again.97 It has also been used in conjunction with electrical stimulation systems in quadriplegic patients to restore some movement.98
The Government of Canada has identified access to timely and appropriate mental health care as essential for Canadians living with mental illness.99 Strategies for improving and managing mental health may be more effective when the person receiving care interacts with a health care provider.100 Applications that use NLP coupled with machine learning algorithms that gather and adapt to new information may help simulate participant-clinician interactions.100-103 Called chatbots, or conversational agents, these programs mimic conversation using text or voice and may also include a virtual, human-like, presence (an embodied conversational agent).100-102
Mental health research has explored using conversational agents to enhance the searchability of online support communities,101 to diagnose major depressive disorder,103 and to deliver cognitive behaviour therapy to people with depression and anxiety.102 A 2017 scoping review100 also identified conversational agents used for autism spectrum disorder and post-traumatic stress disorder.
AI has also been explored as a support or supplement for moderators of an online community for youth mental health.101 When human moderators were not available, programs that assess the sentiment, emotion, and keywords of participant posts were used to recommend appropriate steps and actions.101
In 2018 the Public Health Agency of Canada began exploring the use of AI to help identify communities at increased risk of suicide. AI was used to analyze data from social media posts for suicide-related content to assist in the targeted deployment of mental health resources.104 Similarly, a user reporting system, developed by Facebook, uses AI to automatically alert emergency responders.104 Prediction of suicide and accidental death following hospital discharge using NLP to analyze electronic health records has also been studied in the US.105
Looking into the future, devices that observe, capture, and analyze behaviour in the real world, outside of a clinician’s office, may offer new ways to personalize care.106
Because of its disease prevalence combined with large amounts of readily available data about blood sugar levels and trends, the care of people living with type 1 and type 2 diabetes is emerging as an area of interest for AI researchers.
Artificial neural networks and support vector machine methods have been explored in the development of a screening tool for pre-diabetes.107 The tool used data from a Korean national health survey including nine variables previously used to predict diabetes such as family history, waist circumference, and physical activity. An artificial neural network approach was selected because of its ability to detect complex non-linear relationships.
In the development of artificial pancreas systems,108 a key component is the computer program that connects the readings taken by the continuous glucose monitor to the insulin administered through the insulin pump.109 Researchers have explored the role of AI in supporting these computer programs in personalizing insulin delivery, because of its ability to learn from data in uncertain environments.109
Complications from diabetes are responsible for much of the direct and indirect costs of the disease.110 Researchers in Australia used an artificial neural network to predict these complications while still treatable.110 The artificial neural network models were developed using data from existing surveys that assessed the relationship between risk factors such as hemoglobin A1C and three complication outcomes.
Diabetes is also an area of active machine learning research.111 A 2017 review of biomedical and computer science publications found research on biomarkers for and prediction of future risk of diabetes, diabetes complications, treatment and drug development, genetics, and health systems management.111
As in radiology, specialized vision care relies on the collection and analysis of images.112 In ophthalmology, advances in AI have the potential to disrupt existing vision screening programs and allow for point-of-care diagnosis of patients.112 The use of AI to screen people living with diabetes for diabetic retinopathy has emerged as an area of particular interest.112-116 In April 2018 the FDA approved its first AI enabled device to detect “more than mild” diabetic retinopathy and recommend referral to eye care professionals for appropriate patients.117
Other areas being explored include using deep learning to differentiate healthy eyes from eyes with age-related macular degeneration112 and to predict cardiovascular disease from retinal fundus images,118 as well as using neural networks to automate grading of age-related macular degeneration,119 screening for glaucoma,112 and diagnosis of cataracts.112
Critical care is another clinical specialty that may benefit from AI, particularly since it is an environment that requires clinicians to synthesize data quickly from multiple sources120 in a setting where there is a high degree of stress and uncertainty. 121 Numerous organizations are currently developing tools that leverage machine learning algorithms to predict, for example, the mortality of patients,122 the early onset of sepsis,123 the optimal use of mechanical ventilators,124 and appropriate intravenous fluid requirements.124 It is anticipated that AI may play a role in reducing the average length of stay in an intensive care unit by reducing the time it takes to diagnose and treat patients.125
Population and Public Health
Disease surveillance is an area of interest for AI research because of the availability of text data and information sources already used for traditional monitoring of outbreaks.126-128 Automating the collection, sorting, and analysis of indicators such as country reports, social media posts, and emergency room data for patterns using AI requires less human effort than traditional monitoring and could potentially reduce the time needed to detect an outbreak.126,127 The Public Health Agency of Canada’s Global Public Health Intelligence Network is an example of an early (and still evolving) AI-based surveillance system that has detected early signals for severe acute respiratory syndrome in 2003 and Middle East respiratory syndrome coronavirus in 2012, as just two examples of its successes.129 Using AI to expand the sources of information used for influenza surveillance to include social media posts or Internet searches has also been proposed.127 AI may also help identify populations or areas at risk of diseases such as diabetes or heart disease thereby assisting public health programs to more effectively target education programs.130
Non-Clinical Health-Related Applications
In addition to applications in clinical settings, research into how AI may support or advance non-clinical work in health care is also taking place in areas such as health research and drug discovery and development.
The use of machine learning to advance understanding of the processes that underlie disease is being explored in areas such as genomics and other “omics,” which depend on large volumes of data.1
Machine learning is also being used to discover biomarkers for conditions such as schizophrenia, bipolar disorder, and depression with the hope of improving diagnosis131 or generating hypotheses for future research.132
AI may also impact methods of knowledge synthesis such as systematic reviews and health technology assessments with tasks such as data extraction and searching becoming automated.133,134
Drug Discovery and Development
AI may help assist researchers to identify genetic mutations that cause disease and help predict the effects of treatments.111,135 Applying machine learning to drug development and finding new uses for existing drugs are also being explored.1
The success of AI in health care depends on a number of factors, including the public’s acceptance of AI playing a role in their treatment, the use of patient data, the health care system’s ability to deploy new technology that uses AI, and staff training on how to use the technology.54 While there is great enthusiasm for the improvements that AI is expected to bring to the health care system, there is a need for pragmatic consideration of potential challenges and enablers of optimal AI integration.6 Topics such as cost, data reliance, training requirements, effects on clinicians, clinician-patient relationships, decision transparency, hardware limitations and scaling, and ethical, social, and privacy concerns are addressed below.
Implementation of AI requires resources for hardware and software.2 Recent advances and acceleration of machine learning, and particularly deep learning, make use of computer chips called graphics processing units (GPUs) to rapidly perform required calculations.5,136 GPUs are relatively inexpensive (about US$1,000) and can be added to most computer systems. Thus, a single card can potentially process hundreds of millions of images a day.5 Cloud-based computing services, which provide increased access to low-cost computing power, are also driving advances in AI while lowering costs for organizations.137-140
AI may play a role in the sustainability of a publicly funded health care system by detecting disease earlier141 and providing a more accurate diagnosis.142 The impact of machine learning algorithms that can read and interpret imaging exams has the potential to reduce the cost of analyzing imaging exams and increase the speed in which it takes to review them, allowing far more to be taken over the course of a treatment, wait times permitting.143
AI may bring about improvements in patients outcomes because it supports clinical decision-making and ensures that interventions and treatments are personalized to each patient. This may eradicate costs associated with post-treatment complications.142
Cost savings have been associated with AI applications involving robot-assisted surgery and virtual nursing assistants.144
Misdiagnoses are the leading cause of malpractice claims in Canada. Machine learning may help to reduce health care and legal costs by improving diagnostic accuracy145 and reducing therapeutic errors that occur in the human practice of medicine.8 Conversely, AI technologies may also contribute to misdiagnosis if the performance of the underlying algorithms is not adequate to fulfill the diagnostic task it is assigned.146,147
Data Reliance and Training Requirements
AI systems require large amounts of high-quality data to learn.8,148,149 While it is difficult to determine how much data and training a neural network needs, it is agreed that large datasets are required in order to reach acceptable levels of accuracy and performance.9,40,150 In radiology, for example, machine learning algorithms should be fed by thousands to millions of images.40 As well, algorithms must be trained separately for each condition and disease.40,151 Since the performance of AI systems is dependent on the data used to train them, access to high-quality data is critical. In some instances, clinically relevant datasets may be too small for effective training.149 Additionally, building datasets that are useful for training AI systems often requires skilled experts to accurately label images or other information sources, a time-consuming process that may ultimately limit their availability.17,149
The Centre for International Governance Innovation paper on key elements and policy considerations for a national data strategy in Canada discusses the need for open-structured and secured data sharing, that enables research and development initiatives to utilize the growing amount of digital health information instead of traditional reliance on constrained data capture.152
AI systems have the potential to remove human bias in decision-making, but there remains the risk that, depending on the data used for training algorithms, some models incorporate and reinforce biases from the demographics of the population used for their training.17,153 This bias can be challenging to detect and can unintentionally be incorporated into the logic systems of machine learning products.17,154 The data may not be representative of the target population in which it is being applied which could result in discrimination of legally protected groups in ways hidden from those tasked with making decisions from AI outputs.17 For example, an algorithm may work well in an academic or limited clinical setting, but may not be scalable to a real-world setting, and consequently has the potential to lead to misdiagnosis and harm to patients.153,155 This was demonstrated recently with machine learning software developed for stratifying cancer risk in pulmonary nodules detected with CT imaging. The software attained high performance on the training data set based on patients from the US National Lung Screening Trial but achieved lower performance when applied to patients at Oxford University Hospitals.24
Effects on Clinicians
It has been argued that as machine learning systems evolve, clinicians may become over-reliant on their use and may lose the ability to make informed opinions in their absence.156 While this concern may be valid, it may not differ from the process of adopting any new technology.157
Clinician acceptance of AI and consideration of their experiences and perspectives will be critical for the widespread adoption and implementation of AI in the health care system.6,158,159 Health care providers may perceive that AI reduces their authority and autonomy.17 Introduction of AI systems could also lead to new or changing skill sets as AI systems automate some historically human-centered tasks and incorporate increasingly complex data into patient care.17,160 It is also possible that as more tasks are handed over to AI systems that fewer health care professionals will be needed.6
As the influence and uses of AI expand, a deeper knowledge of health informatics may prove an important skill for health professionals’ understanding of increasingly data-reliant health systems.160
There is concern that some AI applications, such as those that monitor speech or behaviour could change the relationship between patient and clinicians by generating fear that all the data collected could be used and scrutinized for health care decisions.161 Conversely, patient and physician communication may be facilitated with the use of AI by minimizing processing times and in so doing, improving the quality of patient care.6,162 Another consideration is whether AI applications may circumvent or minimize traditional face-to-face patient-clinician interactions.163 Responsibility and liability for misdiagnosis or treatment and its impact on care decisions is a topic of debate.145,146
Before deep learning, using computers to predict outcomes relied on programs in which human experts determined the features to look for and the rules by which these features were to be analyzed.4 Deep learning prediction capabilities are often described as a “black box.” This is because data are processed through hidden layers of decision-making that are often viewed as opaque, with only the output available to the interpreter.2,4,9,150,164
Programs supported by deep learning cannot express reasons why a particular conclusion was made and clinicians cannot tell what inputs were used to come to a decision.4,164 Achieving insight on how decisions are reached is a challenge, not only for clinicians but also for developers of AI systems.165 AI that uses machine learning algorithms based on artificial neural networks may be almost impossible to understand as far as why or how algorithms reach conclusions. Machine learning based on decision trees or Bayesian networks are more transparent to inspection.166 Within a health care context, AI tools must be able to provide evidence as to how they arrive at specific conclusions, allowing physicians to confirm that the conclusion makes sense and course correct if necessary.155 Abstract, hidden layers may also create challenges in comparing and assessing the performance of different AI systems.148
In Europe, the General Data Protection Regulation167 provides individuals with the “right not to be subject to a decision based solely on automated means.”168 The regulation also specifies that individuals should also be provided with meaningful information about how automated systems make their decisions.167
Hardware Limitations and Scaling
Although improvements in computing technology, particularly graphic processing units, have been essential for the expansion of AI applications and research, there are questions about whether hardware improvements will continue at the rate needed to process an ever-expanding volume of health data.1
The standardized nature of AI systems means they can be replicated and scaled and, once trained, a program can be readily deployed across many locations.5 However, there are considerations such as the portability of programs across different systems, scanning machines or acquisition techniques, or the use of different software that may impact how readily and successfully an AI system can be deployed.169,170
Privacy, Social, and Ethical Considerations
In computer science, collaboration and exchange of data sets to improve AI programs are common.24 Making the most of AI in health care may mean clinicians, administrators, and patients shift their expectations regarding control over personal information.24 Backlash against AI is anticipated if the public’s best interest is not considered when these technologies are being developed.17 Maintaining public trust over the use of personal data in a safe and secure way is important for the successful widespread adoption of AI.54 New approaches may be required to assess the ethical acceptability and legitimacy of data science,24 and to develop best practices for data management in AI, including ways of anonymizing data.24
Data Privacy and Security
One challenge is ensuring AI developers working with health care organizations and patient data meet security, data compliance, and audit requirements.171 Possible solutions include having usage agreements and permissions in place for the data being analyzed and commitments to patient data privacy and security.171 There are circumstances where machine learning could inadvertently “leak” private information which could hinder further adoption of AI.171 The Office of the Privacy Commissioner of Canada has issued guidance on obtaining meaningful consent172 and inappropriate data practices173 to support compliance with the Personal Information Protection and Electronics Documents Act (PIPEDA) in the digital age.
Legal and Social Issues
Medicolegal concerns around civil and criminal liability and medical malpractice ¾ for instance, if an AI system misdiagnoses a patient, or if a clinician fails to use an AI system ¾ have also been raised but are as yet unresolved.154
There are concerns that not all parts of the population will benefit equally from AI systems.17 For example, where there is limited data about populations, such as people living with rare diseases or people underrepresented in clinical trials, it may be difficult to collect and consider in a data set.17 At the same time, people living in rural and remote settings may benefit from AI through the use of remote diagnostic applications that can provide real-time prediction of diagnoses and treatments, saving patients from travelling great distances to seek medical advice.174
Ethical questions have been raised around the potential effects of AI on patients.17 While AI applications have the potential to empower people to assess symptoms and provide self-care where appropriate, there are concerns that it could lead to the social isolation of people who would otherwise seek advice from care providers and assistance from family and friends.17 As well, there are concerns around whether AI devices will ensure the dignity, autonomy, and self-determination of users. For example, if an AI tool creates a treatment plan recommending a course of action that a health care provider is unable to explain the logic behind, this may be regarded as an infringement of the patient’s freedom to make informed decisions about their health.17 As well, AI applications that are designed to provide remote care to patients in their homes could lead to confusion by the user around whether they are communicating with a real person or an AI device, which may be perceived as a type of deception or fraud.17
Ethical concerns also relate to the safety of these systems. Currently, industry standards for testing the safety and reliability of AI are not in place in many countries.175 Consequently, there is potential for patient harm if errors are not detected and corrected before diffusion of these technologies.17
Questions have also been raised around the malicious use of AI, particularly its use in covert surveillance or screening,17,176 which could reveal information about a person’s health, without their knowledge, that could potentially be used against them.17
Beyond the potential value and implementation prospects of technological innovations, there are unresolved areas of inquiry regarding the ethical, social, and political challenges with AI. The Wellcome Trust has outlined several areas for future research including the issues of consent, fairness, and rights.6 There is interest in improving understanding of the effect of AI in health care on human relationships, management of data, transparency in decision-making, inequalities, patient preferences, regulation, appropriate use, trust, and the relationship between the private and public sectors involved in the delivery of health care.
Adopting AI into health care will come with challenges, but some promising work has already occurred. To advance innovation and integration of AI in Canada, the Standing Committee on Social Affairs, Science and Technology recommended convening a national conference to bring together government decision-makers with stakeholders.3
1. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. bioRxiv. 2018.
2. Chartrand G, Cheng PM, Vorontsov E, Drozdzal M, Turcotte S, Pal CJ, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37(7):2113-2131.
3. Standing Senate Committee on Social Affairs, Science and Technology. Challenge ahead : integrating robotics, artificial intelligence and 3D printing technologies into Canada’s healthcare systems. Ottawa (ON): Canada Senate; 2017: http://publications.gc.ca/site/eng/9.846477/publication.html. Accessed 2018 May 24.
4. Fogel AL, Kvedar JC. Benefits and risks of machine learning decision support systems. J Am Med Assoc. 2017;318(23):2356.
5. Beam AL, Kohane IS. Translating artificial intelligence into clinical care. J Am Med Assoc. 2016;316(22):2368-2369.
6. Fenech M, Strukelj N, Buston O. Ethical, social, and political challenges of artificial intelligence in health. London (GB): Future Advocacy; 2018: https://wellcome.ac.uk/sites/default/files/ai-in-health-ethical-social-political-challenges.pdf. Accessed 2018 Sep 10.
7. Crown WH. Potential application of machine learning in health outcomes research and some statistical cautions. Value Health. 2015;18(2):137-140.
8. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-243.
9. Mieloszyk RJ, Bhargava P. Convolutional neural networks: The possibilities are almost endless. Curr Probl Diagn Radiol. 2018;47(3):129-130.
10. Mills T. What is natural language processing and what is it used for? 2018; https://www.forbes.com/sites/forbestechcouncil/2018/07/02/what-is-natural-language-processing-and-what-is-it-used-for/#722389015d71. Accessed 2018 Sep 10.
11. SAS Canada. Natural language processing: What it is and why it matters. 2018; https://www.sas.com/en_ca/insights/analytics/what-is-natural-language-processing-nlp.html. Accessed 2018 Sep 10.
12. Reisenwitz C. How deep learning is changing healthcare part 1: Diagnosis. 2017; https://blog.capterra.com/how-deep-learning-is-changing-healthcare-part-1-diagnosis/, 2018 Mar 18.
13. Canadian Association of Radiologists. Artificial intelligence. ; https://car.ca/innovation/artificial-intelligence/. Accessed 2018 Mar 19.
14. CIFAR. Pan-Canadian artificial intelligence strategy. https://www.cifar.ca/ai/pan-canadian-artificial-intelligence-strategy. Accessed 2018 Sep 10.
15. Canadian Institutes of Health Research. Collaborative Health Research Projects (CHRP) with a special call: Artificial intelligence, health and society 2018; http://www.cihr-irsc.gc.ca/e/50922.html. Accessed 2018 Sep 10.
16. The Canadian AI ecosystem: A 2018 profile. Clementi (SG): Green Technology Asia Pte Ltd; 2018: http://www.greentechasia.com/wp-content/uploads/2018/02/Canada-AI-Ecosystem-2018-Profile-Summary-Report-Greentech-Asia.pdf. Accessed 2018 Sep 10.
17. Artificial intelligence (AI) in healthcare and research. London (GB): Nuffield Council on Bioethics; 2018: http://nuffieldbioethics.org/wp-content/uploads/Artificial-Intelligence-AI-in-healthcare-and-research.pdf. Accessed 2018 Sep 10.
18. Health Canada. Notice: Health Canada’s approach to digital health technologies. 2018; https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/notice-digital-health-technologies.html. Accessed 2018 Sep 10.
19. U. S. Food & Drug Administration. Transforming FDA's approach to digital health. 2018; https://www.fda.gov/newsevents/speeches/ucm605697.htm. Accessed 2018 Sep 10.
20. Software as a Medical Device (SAMD): Clinical evaluation - Guidance for industry and Food and Drug Administration staff. Silver Spring (MD): U. S. Food and Drug Administration 2017: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM524904.pdf Accessed 2018 Sep 10.
21. Select Committee on Artificial Intelligence. AI in the UK: ready, willing and able? (Report of session 2017-19). London (GB): House of Lords; 2018: https://publications.parliament.uk/pa/ld201719/ldselect/ldai/100/100.pdf. Accessed 2018 Sep 10.
22. Gottlieb S. Transforming FDA's approach to digital health. 2018; https://www.fda.gov/newsevents/speeches/ucm605697.htm. Accessed 2018 May 24.
23. U. S. Food & Drug Administration. Digital health software precertification (Pre-Cert) program. https://www.fda.gov/medicaldevices/digitalhealth/digitalhealthprecertprogram/default.htm. Accessed 2018 Sep 10.
24. Tang A, Tam R, Cadrin-Chênevert A, Guest W, Chong J, Barfett J, et al. Canadian Association of Radiologists white paper on artificial intelligence in radiology. Can Assoc Radiol J. 2018;69(2):120-135.
25. Molteni M. If you look at x-rays or moles for a living, AI is coming for your job. 2017; https://www.wired.com/2017/01/look-x-rays-moles-living-ai-coming-job/. Accessed 2018 May 24.
26. Disruptive dozen. Cambridge (MA): World Medical Innovation Forum; 2018: https://worldmedicalinnovation.org/wp-content/uploads/2018/04/Partners-FORUM-2018-BROCHURE-D12-AI-180410_1202-FREV2-FOR-WEB-X3.pdf. Accessed 2018 May 24.
27. Suzuki K. Overview of deep learning in medical imaging. Radiol Phys Technol. 2017;10(3):257-273.
28. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data. Radiology. 2016;278(2):563-577.
29. Hatt M, Tixier F, Visvikis D, Cheze Le Rest C. Radiomics in PET/CT: More than meets the eye? J Nucl Med. 2017;58(3):365-366.
30. Krittanawong C, Tunhasiriwet A, Zhang H, Wang Z, Aydar M, Kitai T. Deep learning with unsupervised feature in echocardiographic imaging. J Am Coll Cardiol. 2017;69(16):2100-2101.
31. Brady AP. Error and discrepancy in radiology: inevitable or avoidable? Insights Imaging. 2017;8:171-182.
32. Paredes M. Can artificial intelligence help reduce human medical error? Two examples from ICUs in the US and Peru. 2018; https://techpolicyinstitute.org/wp-content/uploads/2018/02/Paredes-Can-Artificial-Intelligence-help-reduce-human-medical-errors-DRAFT.pdf. Accessed 2018 May 24.
33. Loria K. Putting the AI in radiology. Radiology Today. 2018;19(1).
34. Davenport TH, Dreyer KJ. AI will change radiology, but it won't replace radiologists. Harv Bus Rev. 2018.
35. Medical imaging in the age of artificial intelligence. Erlangen (DE): Siemens; 2017: https://www.siemens.com/press/pool/de/events/2017/healthineers/2017-11-rsna/white-paper-medical-imaging-in-the-age-of-artificial-intelligence.pdf. Accessed 2018 May 24.
36. U.S. Food & Drug Administration. FDA permits marketing of clinical decision support software for alerting providers of a potential stroke in patients. 2018; https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596575.htm. Accessed 2018 May 24.
37. FDAnews. FDA approves marketing AI technology to help diagnose wrist fractures. 2018; https://www.fdanews.com/articles/186983-fda-approves-marketing-ai-technology-to-help-diagnose-wrist-fractures. Accessed 2018 May 24.
38. Harvey H. Nightmare on ML street: the dark potential of AI in radiology. 2017; https://towardsdatascience.com/nightmare-on-ml-street-the-dark-potential-of-ai-in-radiology-71074e70da91. Accessed 2018 May 24.
39. Paiva OA, Prevedello LM. The potential impact of artificial intelligence in radiology. Radiologia brasileira. 2017;50(5):V-vi.
40. The Medical Futurist. The future of radiology and artificial intelligence. 2017; http://medicalfuturist.com/the-future-of-radiology-and-ai/. Accessed 2018 May 24.
41. Auffret M. Industry trends: AI revolutionizes imaging analysis. 2018; http://www.mediantechnologies.com/industry-trends-ai-revolutionizes-imaging-analysis/. Accessed 2018 May 24.
42. Marr B. First FDA approval for clinical cloud-based deep learning in healthcare. 2017; https://www.forbes.com/sites/bernardmarr/2017/01/20/first-fda-approval-for-clinical-cloud-based-deep-learning-in-healthcare/#782e5301161c. Accessed 2018 May 24.
43. Misawa M, Kudo S-e, Mori Y, Cho T, Kataoka S, Yamauchi A, et al. Artificial intelligence-assisted polyp detection for colonoscopy: Initial experience. Gastroenterology. 2018;154(8):2027-2029.
44. Houssami N, Lee CI, Buist DSM, Tao D. Artificial intelligence for breast cancer screening: Opportunity or hype? The Breast. 2017;36:31-33.
45. Kim E-K, Kim H-E, Han K, Kang BJ, Sohn Y-M, Woo OH, et al. Applying data-driven imaging biomarker in mammography for breast cancer screening: Preliminary study. Scientific Reports. 2018;8(1):2762.
46. Feng R, Badgeley M, Mocco J, Oermann E. Deep learning guided stroke management: a review of clinical applications J Neurointerv Surg. 2018;10(4):358-362.
47. Imaging Technology News. Brainomix secures $9.8m investment to tackle strokes with AI. 2018; https://www.itnonline.com/content/brainomix-secures-98m-investment-tackle-strokes-ai. Accessed 2018 May 24.
48. Thornhill RE, Lum C, Jaberi A, Stefanski P, Torres CH, Momoli F, et al. Can shape analysis differentiate free-floating internal carotid artery thrombus from atherosclerotic plaque in patients evaluated with CTA for stroke or transient ischemic attack? Acad Radiol. 2014;21(3):345-354.
49. Chen Y, Dhar R, Heitsch L, Ford A, Fernandez-Cadenas I, Carrera C, et al. Automated quantification of cerebral edema following hemispheric infarction: Application of a machine-learning algorithm to evaluate CSF shifts on serial head CTs. Neuroimage Clin. 2016;12:673-680.
50. Guided Solutions LTD. Artificial intelligence helps improve MRI imaging of strokes. https://www.guidedsolutions.co.uk/GS/NewsDetails/artificial-intelligence-helps-improve-mri-imaging-of-strokes#. Accessed 2018 May 24.
51. Rehme AK, Volz LJ, Feis DL, Bomilcar-Focke I, Liebig T, Eickhoff SB, et al. Identifying neuroimaging markers of motor disability in acute stroke by machine learning techniques. Cereb Cortex. 2015;25(9):3046-3056.
52. Griffis JC, Allendorfer JB, Szaflarski JP. Voxel-based Gaussian naïve Bayes classification of ischemic stroke lesions in individual T1-weighted MRI scans. J Neurosci Methods. 2016;257:97-108.
53. Matthews M. Machine learning can bring more intelligence to radiology 2017; https://www.healthdatamanagement.com/news/machine-learning-can-bring-more-intelligence-to-radiology. Accessed 2018 May 24.
54. Select Committee on Artificial Intelligence. Report of session 2018-19 - AI in the UK: ready, willing and able? (HL Paper 100). London (UK): House of Lords; 2018: https://publications.parliament.uk/pa/ld201719/ldselect/ldai/100/100.pdf. Accessed 2018 May 24.
55. Salvatore C, Battista P, Castiglioni I. Frontiers for the early diagnosis of AD by means of MRI brain imaging and support vector machines. Curr Alzheimer Res. 2016;13(5):509-533.
56. Dallora AL, Eivazzadeh S, Mendes E, Berglund J, Anderberg P. Machine learning and microsimulation techniques on the prognosis of dementia: A systematic literature review. PloS one. 2017;12(6):e0179804.
57. Yoo Y, Tang LW, Brosch T, Li DKB, Metz L, Traboulsee A, et al. Deep learning of brain lesion patterns for predicting future disease activity in patients with early symptoms of multiple sclerosis. In: Carneiro G, ed. Deep learning and data labeling for medical applications (DLMIA 2016; LABELS 2016; Lecture notes in computer science vol. 10008). New York (NY): Springer; 2016: http://www.rogertam.ca/Yoo_MICCAI_DLMIA_2016.pdf. Accessed 2018 May 24.
58. Salvatore C, Cerasa A, Castiglioni I, Gallivanone F, Augimeri A, Lopez M, et al. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. J Neurosci Methods. 2014;222:230-237.
59. Dillon J. Artificial intelligence arrives in GI 2018; https://www.gastroendonews.com/Article/PrintArticle?articleID=46584. Accessed 2018 Sep 10.
60. Densford F. Olympus inks co-development deal with Ai4gi for AI-supported colonoscopy solution. 2018; https://www.massdevice.com/olympus-inks-co-development-deal-with-ai4gi-for-ai-supported-colonoscopy-solution/. Accessed 2018 Sep 10.
61. Harvey H. Can AI enable a 10 minute MRI? 2018; https://towardsdatascience.com/can-ai-enable-a-10-minute-mri-77218f0121fe. Accessed 2018 May 24.
62. Golden JA. Deep learning algorithms for detection of lymph node metastases from breast cancer: Helping artificial intelligence be seen. J Am Med Assoc. 2017;318(22):2184-2186.
63. Janowczyk A, Madabhushi A. Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases J Pathol Inform. 2016;7(29).
64. MacDonald A. The role of AI in pathology 2017; https://www.technologynetworks.com/diagnostics/articles/the-role-of-ai-in-pathology-290609. Accessed 2018 May 24.
65. The Medical Futurist. The digital future of pathology. 2018; http://medicalfuturist.com/digital-future-pathology/. Accessed 2018 May 24.
66. Burt J. Deep learning is the next platform for pathology. 2018; https://www.nextplatform.com/2018/01/31/pathology-next-platform-deep-learning/. Accessed 2018 May 24.
67. Sandle T. Artificial intelligence is aiding pathologists. 2017; http://www.digitaljournal.com/tech-and-science/science/pathologists-spotting-disease-better-with-artificial-intelligence/article/501476#ixzz5EvmOAx00. Accessed 2018 May 24.
68. Startups bring AI to pathology. Cancer Discov. 2018;8(4):376.
69. Mobadersany P, Yousefi S, Amgad M, Gutman DA, Barnholtz-Sloan JS, Velasquez Vega JE, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci U S A. 2018;115(13):E2970-2979.
70. Sennaar K. Machine learning for dermatology – 5 current applications. 2018; https://www.techemergence.com/machine-learning-dermatology-applications/. Accessed 2018 May 24.
71. Gareau DS, Correa da Rosa J, Yagerman S, Carucci JA, Gulati N, Hueto F, et al. Digital imaging biomarkers feed machine learning for melanoma screening. Exp Dermatol. 2017;26(7):615-618.
72. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115-118.
73. Singh R. Dermatology and its future with AI. 2017; https://kivihealth.com/blog/dermatology-artificial-intelligence/. Accessed 2018 May 24.
74. Han SS, Park GH, Lim W, Kim MS, Na JI, Park I, et al. Deep neural networks show an equivalent and often superior performance to dermatologists in onychomycosis diagnosis: Automatic construction of onychomycosis datasets by region-based convolutional deep neural network. PloS one. 2018;13(1):e0191493.
75. Mesko B. The role of artificial intelligence in precision medicine. Expert Rev Precis Med Drug Dev. 2017;2(5):239-241.
76. Williams AM, Liu Y, Regner KR, Jotterand F, Liu P, Liang M. Artificial intelligence, physiological genomics, and precision medicine. Physiol Genomics. 2018;50(4):237-243.
77. Libbrecht MW. Machine learning in genetics and genomics. Nature Reviews Genetics. 2015;16:321-332.
78. Pauwels E. Your DNA avatar – What happens when artificial intelligence meets cutting-edge genetics? 2017; https://www.wilsoncenter.org/blog-post/your-dna-avatar-what-happens-when-artificial-intelligence-meets-cutting-edge-genetics. Accessed 2018 May 24.
79. Fernandez CR. Combining liquid biopsy and artificial intelligence to outrun cancer. 2018; https://labiotech.eu/cambridge-cancer-genomics-liquid-biopsy-ai/. Accessed 2018 May 24.
80. World Economic Forum. How to optimize human biology. 2017; https://www.weforum.org/agenda/2017/11/how-to-optimize-human-biology. Accessed 2018 May 24.
81. Gaskell A. How AI can make editing CRISPR safer. 2018; https://dzone.com/articles/how-ai-can-make-editing-crispr-safer. Accessed 2018 May 24.
82. Cookson C. UK scientists edit genome to change human embryo development. 2017; https://www.ft.com/content/54908014-9dff-11e7-9a86-4d5a475ba4c5. Accessed 2018 May 24.
83. Johnson W, Pauwels E. How to optimize human biology: where genome editing and artificial intelligence collide. Washington (DC): Wilson Center; 2017: https://www.scribd.com/document/361235830/How-to-Optimize-Human-Biology-Where-Genome-Editing-and-Artificial-Intelligence-Collide. Accessed 2018 May 24.
84. Sriharan K. Artificial intelligence in oncology. 2018; https://blog.oup.com/2018/03/artificial-intelligence-oncology/. Accessed 2018 May 24.
85. Rouse M. Cognitive computing 2016; https://searchenterpriseai.techtarget.com/definition/cognitive-computing. Accessed 2018 May 24.
86. Locklear M. IBM’s Watson is really good at creating cancer treatment plans. 2017; https://www.engadget.com/2017/06/01/ibm-watson-cancer-treatment-plans/. Accessed 2018 May 24.
87. Curioni-Fontecedro A. A new era of oncology through artificial intelligence. ESMO open. 2017;2(2):e000198.
88. Kantarjian H, Yu PP. Artificial intelligence, big data, and cancer. JAMA Oncology. 2015;1(5):573-574.
89. Charnow JA. Cognitive computing expedites matching patients to clinical trials. 2017; https://www.oncologynurseadvisor.com/asco-2017/using-the-ibm-watson-system-to-aid-ctm/article/666580/. Accessed 2018 May 24.
90. Norden AD, Dankwa-Mullen I, Urman A, Suarez F, Rhee K. Realizing the promise of cognitive computing in cancer care: Ushering in a new era JCO Clin Cancer Inform. 2018;2:1-6.
91. Patel NM, Michelini VV, Snell JM, Balu S, Hoyle AP, Parker JS, et al. Enhancing next‐generation sequencing‐guided cancer care through cognitive computing. The Oncologist. 2017;23(2):178-185.
92. Vu MT, Adali T, Ba D, Buzsaki G, Carlson D, Heller K, et al. A shared vision for machine learning in neuroscience. J Neurosci. 2018;38(7):1601-1607.
93. Villar JR, Gonzalez S, Sedano J, Chira C, Trejo-Gabriel-Galan JM. Improving human activity recognition and its application in early stroke diagnosis. Int J Neural Syst. 2015;24(4).
94. Mannini A, Trojaniello D, Cereatti A, Sabatini AM. A machine learning framework for gait classification using inertial sensors: Application to elderly, post-stroke and Huntington’s disease patients. Sensors. 2016;16(1):134.
95. Zhang Q, Xie Y, Ye P, Pang C. Acute ischaemic stroke prediction from physiological time series patterns. Australas Med J. 2013;6(5):280-286.
96. Zhan A, Mohan S, Tarolli C, Schneider R, Adams J, Sharma S, et al. Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurol. 2018.
97. Sandle T. Artificial intelligence helps stroke patients walk again. 2017; http://www.digitaljournal.com/tech-and-science/science/artificial-intelligence-helps-stroke-patients-walk-again/article/498356. Accessed 2018 May 24.
98. Bouton CE, Shaikhouni A, Annetta NV, Bockbrader MA, Friedenberg DA, Nielson DM, et al. Restoring cortical control of functional movement in a human with quadriplegia. Nature. 2016;533:247-250.
99. Chapter 3 - A strong Canada at home and in the world. Building a stronger middle class. Ottawa (ON): Government of Canada; 2017: https://www.budget.gc.ca/2017/docs/plan/chap-03-en.html. Accessed 2018 May 24.
100. Provoost S, Lau HM, Ruwaard J, Riper H. Embodied conversational agents in clinical psychology: A scoping review. J Med Internet Res. 2017;19(5):e151.
101. D'Alfonso S, Santesteban-Echarri O, Rice S, Wadley G, Lederman R, Miles C, et al. Artificial intelligence-assisted online social therapy for youth mental health. Front Psychol. 2017;8:796.
102. Fitzpatrick KK, Darcy A, Vierhile M. Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (Woebot): A randomized controlled trial. JMIR Ment Health. 2017;4(2):e19.
103. Philip P, Micoulaud-Franchi JA, Sagaspe P, Sevin E, Olive J, Bioulac S, et al. Virtual human as a new diagnostic tool, a proof of concept study in the field of major depressive disorders. Sci Rep. 2017;7:42656.
104. Kennedy S, Fonseka TM. How AI is helping to predict and prevent suicides. 2018; https://www.macleans.ca/society/how-ai-is-helping-to-predict-and-prevent-suicides/. Accessed 2018 May 24.
105. McCoy TH, Jr., Castro VM, Roberson AM, Snapper LA, Perlis RH. Improving prediction of suicide and accidental death after discharge from general hospitals with natural language processing. JAMA psychiatry. 2016;73(10):1064-1071.
106. Louie AK, Balon R, Beresin EV, Coverdale JH, Brenner AM, Guerrero APS, et al. Teaching to see behaviors-using machine learning? Acad Psychiatry. 2017;41(5):625-630.
107. Choi SB, Kim WJ, Yoo TK, Park JS, Chung JW, Lee YH, et al. Screening for prediabetes using machine learning models. Comput Math Methods Med. 2014;2014:618976.
108. A hybrid closed-loop insulin delivery system for the treatment of type 1 diabetes. (CADTH Issues in emerging health technologies no. 155). Ottawa (ON): CADTH; 2017: https://cadth.ca/sites/default/files/pdf/eh0052_hybrid_closed-loop_insulin_delivery_system_for_the_treatment_of_type_1_diabetes.pdf. Accessed 2018 May 24.
109. Daskalaki E, Diem P, Mougiakakou SG. Model-free machine learning in biomedicine: Feasibility study in type 1 diabetes. PloS one. 2016;11(7):e0158722.
110. Sangi M, Win KT, Shirvani F, Namazi-Rad MR, Shukla N. Applying a novel combination of techniques to develop a predictive model for diabetes complications. PloS one. 2015;10(4):e0121569.
111. Kavakiotis I, Tsave O, Salifoglou A, Maglaveras N, Vlahavas I, Chouvarda I. Machine learning and data mining methods in diabetes research. Comput Struct Biotechnol J. 2017;15:104-116.
112. Lee A, Taylor P, Kalpathy-Cramer J, Tufail A. Machine learning has arrived! Ophthalmology. 2017;124(12):1726-1728.
113. Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. J Am Med Assoc. 2016;316(22):2402-2410.
114. Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. J Am Med Assoc. 2017;318(22):2211-2223.
115. Tufail A, Rudisill C, Egan C, Kapetanakis VV, Salas-Vega S, Owen CG, et al. Automated diabetic retinopathy image assessment software: Diagnostic accuracy and cost-effectiveness compared with human graders. Ophthalmology. 2017;124(3):343-351.
116. Wong TY, Bressler NM. Artificial intelligence with deep learning technology looks into diabetic retinopathy screening. J Am Med Assoc. 2016;316(22):2366-2367.
117. U.S. Food & Drug Administration. FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems. 2018; https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604357.htm, 2018 May 24.
118. Poplin R, Varadarajan AV, Blumer K, Liu Y, McConnell MV, Corrado GS, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. Nat Biomed Eng. 2018;2(3):158-164.
119. Burlina PM, Joshi N, Pekala M, Pacheco KD, Freund DE, Bressler NM. Automated grading of age-related macular degeneration from color fundus images using deep convolutional neural networks. JAMA Ophthalmol. 2017;135(11):1170-1176.
120. Baronov D, Etiometry CTO. The role of artificial intelligence in ICUs. 2017; http://www.etiometry.com/2017/04/05/the-role-of-artificial-intelligence-in-icus/. Accessed 2018 Sep 10.
121. Lighthall GK, Vazquez-Guillamet C. Understanding decision making in critical care. Clin Med Res. 2015;13(3-4):156-168.
122. Cordero AS. Would you trust your life to an 'autopilot' robo-doctor? 2017; https://www.wired.co.uk/article/autodoctor-artificial-intelligence-healthcare. Accessed 2018 Sep 10.
123. Livernois C. AI predicts early onset of sepsis 2018; https://www.clinical-innovation.com/topics/artificial-intelligence/ai-predicts-early-onset-sepsis. Accessed 2018 Sep 10.
124. Strickland E. In hospital ICUs, AI could predict which patients are likely to die. 2017; https://spectrum.ieee.org/the-human-os/biomedical/diagnostics/in-hospital-intensive-care-units-ai-could-predict-which-patients-are-likely-to-die. Accessed 2018 Sep 10.
125. Hadar T. Predictive care startup Intensix harnesses AI to help intensive care units run better. 2017; https://www.calcalistech.com/ctech/articles/0,7340,L-3726142,00.html. Accessed 2018 Sep 10.
126. McKay S, Bali S. Disruptive technologies: Keeping an AI on disease surveillance. 2018; https://www.globalhealthnow.org/2018-04/disruptive-technologies-keeping-ai-disease-surveillance. Accessed 2018 May 24.
127. The great promise of artificial intelligence for public health. 2018; http://yfile.news.yorku.ca/2018/04/05/the-great-promise-of-artificial-intelligence-for-public-health/. Accessed 2018 May 24.
128. Neill DB. New directions in artificial intelligence for public health surveillance. IEEE Intelligent Systems. 2012;27(1):56-59.
129. Dion M, AbdelMalik P, Mawudeku A. Big Data and the Global Public Health Intelligence Network (GPHIN). Can Commun Dis Rep. 2015;41(9):209-214.
130. Bostic B. Using artificial intelligence to solve public health problems. 2018; https://www.beckershospitalreview.com/healthcare-information-technology/using-artificial-intelligence-to-solve-public-health-problems.html. Accessed 2018 May 24.
131. Pinto JV, Passos IC, Gomes F, Reckziegel R, Kapczinski F, Mwangi B, et al. Peripheral biomarker signatures of bipolar disorder and schizophrenia: A machine learning approach. Schizophrenia research. 2017;188:182-184.
132. Dipnall JF, Pasco JA, Berk M, Williams LJ, Dodd S, Jacka FN, et al. Fusing data mining, machine learning and traditional statistics to detect biomarkers associated with depression. PloS one. 2016;11(2):e0148195.
133. O'Connor AM, Tsafnat G, Gilbert SB, Thayer KA, Wolfe MS. Moving toward the automation of the systematic review process: a summary of discussions at the second meeting of International Collaboration for the Automation of Systematic Reviews (ICASR). Systematic reviews. 2018;7(1):3.
134. Beller E, Clark J, Tsafnat G, Adams C, Diehl H, Lund H, et al. Making progress with the automation of systematic reviews: principles of the International Collaboration for the Automation of Systematic Reviews (ICASR). Systematic reviews. 2018;7(1):77.
135. Cooderham M. Faster. Cheaper. Better. The Future of Artificial Intelligence. Toronto: MaRS Discovery District; : https://www.marsdd.com/wp-content/uploads/2017/12/MaRS_Final_AI_Magazine_HighRes.pdf. Accessed 2018 May 24.
136. Fraenkel B. For machine learning, it's all about GPUs. 2017; https://www.forbes.com/sites/forbestechcouncil/2017/12/01/for-machine-learning-its-all-about-gpus/#32e7611c7699. Accessed 2018 Sep 10.
137. Buest R. AI becomes the game changer in the public cloud. 2018; https://www.cio.com/article/3250861/artificial-intelligence/ai-becomes-the-game-changer-in-the-public-cloud.html.
138. Raja A. How is the cloud enabling artificial intelligence? 2018; https://www.atlantic.net/cloud-hosting/cloud-enabling-artificial-intelligence/. Accessed 2018 Sep 10.
139. Ismail N. The combination of artificial intelligence and the cloud. 2018; https://www.information-age.com/combination-artificial-intelligence-cloud-123470999/. Accessed 2018 Sep 10.
140. MSV J. The rise of artificial intelligence as a service in the public cloud. 2018; https://www.forbes.com/sites/janakirammsv/2018/02/22/the-rise-of-artificial-intelligence-as-a-service-in-the-public-cloud/#304a1bc6198e.
141. Ghosh P. AI early diagnosis could save heart and cancer patients. 2018; https://www.bbc.com/news/health-42357257. Accessed 2018 May 24.
142. Bernaert A, Akpakwu E. Four ways AI can make healthcare more efficient and affordable. 2018; https://www.weforum.org/agenda/2018/05/four-ways-ai-is-bringing-down-the-cost-of-healthcare. Accessed 2018 May 24.
143. Jung K-HJ, Park HP, Hwang W. Deep learning for medical image analysis: Applications to computed tomography and magnetic resonance imaging. Hanyang Medical Reviews. 2017;37:61-70.
144. Saince. The cost of care: how AI is revolutionizing healthcare and driving down prices. 2017; http://www.saince.com/cost-care-ai-revolutionizing-healthcare-driving-prices/. Accessed 2018 May 24.
145. Greenberg A. Artificial intelligence in health care: Are the legal algorithms ready for the future? McGill Journal of Law and Health. 2017.
146. Dilsizian SE, Siegel EL. Artificial Intelligence in Medicine and Cardiac Imaging: Harnessing Big Data and Advanced Computing to Provide Personalized Medical Diagnosis and Treatment. Curr Cardiol Rep. 2013;16(1):441.
147. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. Nature Reviews Cancer. 2018;18(8):500-510.
148. Artificial intelligence in health care: within touching distance. Lancet. 2018;390(10114):2739.
149. Artificial intelligence for health and health care. (JSR-17-Task-002). McLean (VA): The Mitre Corporation; 2017: https://www.healthit.gov/sites/default/files/jsr-17-task-002_aiforhealthandhealthcare12122017.pdf.
150. Hingorani R, Hansen CL. Can machine learning spin straw into gold? J Nucl Cardiol. 2017.
151. Hainc N, Federau C, Stieltjes B, Blatow M, Bink A, Stippich C. The bright, artificial intelligence-augmented future of neuroimaging reading. Front Neurol. 2017;8(489).
152. A national data strategy for Canada: Key elements and policy considerations. (CIGI Papers No. 160). Waterloo (ON): Centre for International Governance Innovation; 2018: https://www.cigionline.org/sites/default/files/documents/Paper%20no.160_3.pdf. Accessed 2018 Sep 10.
153. Forsting M. Machine learning will change medicine. J Nucl Med. 2017;58(3):357-358.
154. Baker MW, Bearman D. “Paging Dr. Bot” – the emergence of AI and machine learning in healthcare ABA Health eSource. 2017;14(2).
155. Tiwari R. 5 Tips for assessing AI and machine learning tools for health care. 2017; https://www.beckershospitalreview.com/healthcare-information-technology/5-tips-for-assessing-ai-and-machine-learning-tools-for-health-care.html. Accessed 2018 May 24.
156. Cabitza F, Rasoini R, Gensini GF. Unintended consequences of machine learning in medicine. J Am Med Assoc. 2017;318(6):517-518.
157. Berner ES, Ozaydin B. Benefits and risks of machine learning decision support systems. J Am Med Assoc. 2017;318(23):2353-2354.
158. Keel S, Lee PY, Scheetz J, Li Z, Kotowicz MA, MacIsaac RJ, et al. Feasibility and patient acceptability of a novel artificial intelligence-based screening model for diabetic retinopathy at endocrinology outpatient services: a pilot study. Scientific Reports. 2018;8(1):4330.
159. Bonderman D. Artificial intelligence in cardiology. Wien Klin Wochenschr. 2017;129(23):866-868.
160. Fridsma DB. Health informatics: a required skill for 21st century clinicians. BMJ. 2018;362.
161. Kay J. Computers are already better than doctors at diagnosing some diseases. https://www.marsdd.com/magazine/computers-are-already-better-than-doctors-at-diagnosing-some-diseases/. Accessed 2018 May 24.
162. Krittanawong C. Healthcare in the 21st century. Eur J Intern Med. 2017;38:e17.
163. Meskó B, Hetényi G, Győrffy Z. Will artificial intelligence solve the human resource crisis in healthcare? BMC Health Serv Res. 2018;18(1):545.
164. Faggella D. Maching learning healthcare applications - 2018 and beyond. 2018; https://www.techemergence.com/machine-learning-healthcare-applications/. Accessed 2018 May 23.
165. Sentient. Understanding the ‘black box’ of artificial intelligence. 2018; https://www.sentient.ai/blog/understanding-black-box-artificial-intelligence/. Accessed 2018 Sep 10.
166. Bostrom N, Yudkowsky E. The Ethics of artificial intelligence. Berkeley (CA): Machine Intelligence Research Institute; : https://intelligence.org/files/EthicsofAI.pdf. Accessed 2018 Sep 10.
167. Council of the European Union, European Parliament. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). 2016; https://publications.europa.eu/en/publication-detail/-/publication/3e485e15-11bd-11e6-ba9a-01aa75ed71a1/language-en. Accessed 2018 Sep 10.
168. European Commission. Can I be subject to automated individual decision-making, including profiling? https://ec.europa.eu/info/law/law-topic/data-protection/reform/rights-citizens/my-rights/can-i-be-subject-automated-individual-decision-making-including-profiling_en. Accessed 2018 Sep 10.
169. Hassanzadeh H, Nguyen A, Karimi S, Chu K. Transferability of artificial neural networks for clinical document classification across hospitals: A case study on abnormality detection from radiology reports. J Biomed Inform. 2018.
170. Tyukin IY, Gorban AN, Sofeykov KI, Romanenko I. Knowledge transfer between artificial intelligence systems. Front Neurorobot. 2018;12:49.
171. Siwicki B. What hospitals should consider when choosing AI tools. 2017; http://www.healthcareitnews.com/news/what-hospitals-should-consider-when-choosing-ai-tools. Accessed 2018 May 24.
172. Office of the Privacy Commissioner of Canada. Guidelines for obtaining meaningful consent. 2018; https://www.priv.gc.ca/en/privacy-topics/collecting-personal-information/consent/gl_omc_201805/. Accessed 2018 Sep 10.
173. Office of the Privacy Commissioner of Canada. Guidance on inappropriate data practices: Interpretation and application of subsection 5(3). 2018; https://www.priv.gc.ca/en/privacy-topics/collecting-personal-information/consent/gd_53_201805/. Accessed 2018 Sep 10.
174. Lannquist Y. Ethical & policy risks of artificial intelligence in healthcare. 2018; http://www.thefuturesociety.org/ethical-policy-risks-of-artificial-intelligence-in-healthcare/.
175. Lufkin B. Why the biggest challenge facing AI is a ethical one. 2017; http://www.bbc.com/future/story/20170307-the-ethical-challenge-facing-artificial-intelligence?obOrigUrl=true. Accessed 2018 Sep 10.
176. LeVine S. Orwellian surveillance is changing us, and it's powered by AI. 2018; https://www.axios.com/ai-geopolitics-surveillance-nightmare-db613f44-0d3f-4496-8442-905c9a297658.html. Accessed 2018 Sep 10.
About this Document
Authors: Jeff Mason, Andra Morrison, Sarah Visintini
Acknowledgements: Alison Sinclair, Teo Quay, Lesley Dunfield, Iryna Magega
Cite As: An Overview of Clinical Applications of Artificial Intelligence. Ottawa: CADTH; 2018 Sep. (CADTH issues in emerging health technologies; issue 174)
ISSN: 1488-6324 (online)
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care
of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While CADTH has taken care to ensure that the information prepared by it in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the
third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. You are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Contact email@example.com with inquiries about this notice or legal matters relating to CADTH services.